Recruitment completion for 2R2
The 2R2 Study is a Phase 2 clinical trial to evaluate the completion of treatment and safety of short-course (2-months) high-dose rifampicin regimen compared with standard 4-month treatment with rifampicin to treat TB infection.
This study is underway in Vietnam, Indonesia and Canada. In Vietnam, 460 people have been enrolled. These were contacts of active tuberculosis patients, HIV-infected people, diabetics and medical staff. Participating sites include Hanoi Lung Hospital, Hai Ba Trung District Medical Center, The Medical Center of Nam Tu Liem District (Hanoi), and Phoi Viet: Center of Respiratory Diseases Treatment (HCMC).
Despite facing many difficulties in the start-up phase, including being interrupted by the COVID-19 pandemic, Vietnam was the first country to complete its recruitment target of sample in July 2022. These 460 participants will continue to be followed for 26 months.